OClawVPS.com
SPRIM Ventures
Edit

SPRIM Ventures

https://www.sprim.com
Last activity: 09.01.2026
Active
Invests in categories: ResearchTechnologyHealthTechScienceDiagnosticsPlatformDataAppProductMedTech
SPRIM has more than 450 people in 17 offices across six continents. We focus on discovering and implementing new ideas to deliver better health. Large multi-national companies, startups, institutions, and governments around the world turn to us for help developing relevant, fresh and meaningful health innovations. From traditional categories like nutrition, cosmetics, personal care and pharmaceuticals to the new health frontier of digital-connected devices and algorithm-based diagnostics, we work to deliver winning health solutions and tangible commercial results.

In 2017, SPRIM and Tikehau Capital launched TKS 1, a venture capital fund designed to support early-stage, healthcare tech companies. TKS 1 provides capital to innovative companies offering solutions that move science forward in the health sector, contribute to the transition from intervention to prediction, and enable life science companies globally to develop therapeutics faster and more economically.
Likes
278
Portfolio
7
Mentions
13
Location: United States, Florida, Orlando
Employees: 201-500
Founded date: 2001
Investment Type: Venture Capital
Investment Stage: Pre-Seed; Seed; Series A

Portfolio 7

DateNameWebsiteTotal RaisedLocation
28.08.2025Vaxxasvaxxas.com$128.76MAustralia
-ObjectiveH...objectivegi.com$6.6MUnited Sta...
-ObvioHealt...obviohealth.com$48MUnited Sta...
-1nHealth1nhealth.com-United Sta...
-Evid Scien...evidscience.com-United Sta...
-Fibronosti...fibronostics.com$8MUnited Sta...
-RegASKregask.com$10MSingapore

Mentions in press and media 13

DateTitleDescription
09.01.2026KAHR Bio: $22 Million Raised And Phase 2 Topline Data For DSP107 Combo In MSS Colorectal CancerKAHR Bio announced it posted “strong” topline results from a Phase 2a dose-expansion cohort evaluating its investigational immunotherapy DSP107 in combination with Roche’s atezolizumab (Tecentriq) in late-line metastatic microsatellite stab...
28.08.2025Vaxxas: A$90 Million Secured For Commercializing Needle-Free Vaccination Delivery TechnologyVaxxas, a biotechnology company developing the high-density microarray patch (HD-MAP) for needle-free vaccine delivery, has secured approximately $90 million in its latest financing round. This funding, one of the largest in Australia for a...
22.02.2024Las Jornadas Internacionales de Nutrición Práctica están de vueltaJornadas de Nutrición Práctica Las Jornadas de Nutrición Práctica y el Congreso Internacional de SEDCA son el punto de encuentro para actualizar y poner sobre la mesa todos los temas en materia de salud, nutrición y alimentación” — Dr. Anto...
12.02.2024CINFA CELEBRATES ITS 10 YEARS OF PRESENCE IN KUWAIT WITH A STRONG COMMITMENT TO HEALTH AND WELL-BEINGCinfa with the Spanish ambassador in Kuwait, local distributors and sales KUWAIT, February 12, 2024 /EINPresswire.com/ -- • Cinfa has celebrated its 10th anniversary of positive impact and collaboration to improve the well-being and health ...
12.02.2024سينفا يحتفل بمرور 10 سنوات على تواجده في الكويت مع التزامه القوي بالصحة والرفاهيةCinfa with the Spanish ambassador in Kuwait, local distributors and sales KUWAIT, February 12, 2024 /EINPresswire.com/ -- • احتفل مختبر سينفا Cinfa بالذكرى العاشرة للتأثير الإيجابي والتعاون لتحسين رفاهية الكويتيين وصحتهم من خلال توفير حلول ...
17.01.2024Singapore's SPRIM Global anchors $21m funding in Australia's Prota TherapeuticsSPRIM Global Investments, a Singapore-based health sciences venture capital firm, has led the $21-million equity and debt financing in Australian biotech company Prota Therapeutics, according to an announcement.
17.01.2024SPRIM Global Investments led $21 M Debt & Equity funding raised by Prota TherapeuticsProta Therapeutics Pty Ltd (Prota), an Australian biotechnology company, announced that it has raised $21 million in debt and equity financing. Prota is focused on developing innovative oral immunotherapy treatments that induce allergy remi...
13.10.2021AUM Biosciences announces closing of USD $27Million in a "Series A" Round of funding to advance its clinical stage pipeline of precision and targeted cancer therapiesSINGAPORE, Oct. 13, 2021 /PRNewswire/ -- AUM Biosciences (AUM) today announced the successful completion of USD $27 million series A funding round. This will fuel AUM's vision of developing a world class biotech pipeline focused on drugging...
12.10.2021AUM Biosciences announces closing of $27 million in a “Series A” Round of funding to advance its clinical stage pipeline of precision and targeted cancer therapiesSINGAPORE and NEW YORK, October 12, 2021 – AUM Biosciences (AUM) today announced the successful completion of $27 million series A funding round. This will fuel AUM’s vision of developing a world class biotech pipeline focused on drugging w...
01.07.2021ObvioHealth Raises $31 Million, Adds Two Strategic Partners to Bolster Capabilities and Drive Growth Globally NEW YORK –July 1, 2021 – ObvioHealth, a global Virtual Research Organization(VRO), announces it has raised $31 million in its latest round of financing. The round was led by two new partners: Dedalus Group, an international healthcare IT ...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In